Drug Trial Radar · NCT07061938
Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
34
Planned (sponsor's estimate)
Start
Jan 1, 2026
Primary completion
Sep 20, 2029
Study completion Sep 20, 2029
Sponsor
- Lead sponsor
- Acepodia Biotech, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 14, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
Conditions
- IgG4 Related Disease
Interventions
ACE1831Drug
ACE1831 is allogeneic gamma delta T (gdT) cell therapy. Subjects will receive ACE1831 dose based on the assigned dose escalation cohort.
Lymphodepleting chemotherapyDrug
Subjects assigned to receive lymphodepleting preconditioning (LDC) will receive chemotherapy (fludarabine and cyclophosphamide) ahead of ACE1831 administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability of ACE1831 as Assessed by Adverse Events, Clinical Laboratory Tests, Physical Examinations, ECGs, and Vital SignsTime frame: up to 72 weeks post first-ACE1831 dose
Locations
11 sites in 3 countries. Site status is shown where the registry gives one.
Emory University
Atlanta, Georgia
Massachusetts General Hospital
Boston, Massachusetts
Beijing Friendship Hospital
Beijing, China
Peking Union Medical College Hospital
Beijing, China
Sichuan University - West China Hospital
Chengdu, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, China
The First Affiliated Hospital-University of Science and Technology of China
Hefei, China
Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Shanghai, China
Bethune Hospital Shanxi Academy of Medical Sciences
Taiyuan, China
Huazhong University of Science and Technology-Tongji Hospital (TJH)
Wuhan, China
Kanazawa Medical University Hospital
Kahoku-gun, JP, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.